Regeneron Pharmaceuticals
$734.81Change from previous close: −3.09%Absolute change: −$23.46
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $75.65B
- Enterprise value
- $68.09B
- P/E (trailing 12 months)
- 18.2
- Forward P/E
- 11.9
- PEG
- 1.36
- Price/book
- 2.32
- Price/sales
- 4.87
- EV/EBITDA
- 14.5
- EV/revenue
- 4.38
Profitability and growth
- Gross margin
- 44.5%
- Operating margin
- 33.1%
- Net margin
- 27.9%
- ROE
- 14.0%
- ROA
- 6.5%
- Revenue growth (year over year)
- 16.7%
- Earnings growth (year over year)
- -4.5%
Financial health
- Total cash
- $7.99B
- Total debt
- $2.71B
- Debt/equity
- 0.09
- Current ratio
- 3.34
- Quick ratio
- 2.63
Dividends
- Annual dividend per share
- $3.76
- Dividend yield
- 0.5%
- Payout ratio
- 9.0%
- Ex-dividend date
- August 18, 2026
Analysts and estimates
- Average price target
- $853.19
- Median price target
- $857.00
- High price target
- $1,030.00
- Low price target
- $730.00
- Analysts with a price target
- 26
- Consensus
- Buy
- Forward EPS
- $61.51
- EPS estimate, current year
- $54.80
Shares and trading
- Beta
- 0.19
- Average volume
- 748.7K
- Shares outstanding
- 101.14M
- Float
- 95.85M
- Institutional ownership
- 93.5%
- Insider ownership
- 2.1%
- Short interest (% of float)
- 2.6%
- Short ratio (days)
- 4.04